Low-dose interleukin 2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial. (2022)

First Author: Sriranjan R
Attributed to:  Low dose interleukin (IL)-2 in patients with a recent acute coronary syndrome funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.17863/cam.90419

Publication URI: https://www.repository.cam.ac.uk/handle/1810/343005

Type: Journal Article/Review